Laurenţiu Scheuşan, who has been recently appointed as head overa seven-country region with Alvogen US drug maker, says Romania hasbecome a regional centre for the company, meaning the activity inthis area will be coordinated from the domestic market.
Last year, the first operational year for the company inRomania, turnover hit 1.9m dollars, while for this year the targetwas raised to 6m dollars.
Scheuşan wants Romanian turnover to reach 35-30m dollars in2015.
"There will be organic growth, but as competition is very tight atpresent, if we want to grow we must also consider acquisitions.However, there will not be large acquisitions and we targetmedium-sized companies. In Romania, I looked (to buy a company),but I haven't found any opportunity to present to the board,"Scheuşan, sales executive vice-president in CEE with Alvogen, toldZF.
"(...) Unfortunately, I have no argument to present to the boardfor a greenfield investment in Romania (...)," Scheuşan said.
Pentru alte știri, analize, articole și informații din business în timp real urmărește Ziarul Financiar pe WhatsApp Channels
